DOCSLIB.ORG

Australian Dementia Forum 2021 1

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Australian Dementia Forum 2021 1 Australian Dementia Forum 2021 1 Australian Dementia Forum 2021 31 May – 1 June Virtual Handbook www.adf2021.org.au [email protected] The Australian Dementia Network Dementia is a major and growing health issue for Australians. In 2020, an estimated 459,000 people are living with dementia and this number is growing by about 250 persons each day. Dementia is the second leading cause of death of Australians and is the single greatest cause of disability in Australians aged 65 and over. It is estimated to cost the nation more than $15 billion annually. The Australian Dementia Network (ADNeT) brings together Australia’s leading scientists, researchers, and clinicians into the largest national network of experts in Alzheimer’s disease and other forms of dementia. Through our research, we strive to improve the quality of clinical care for people with dementia and mild cognitive impairment Use the conference social and accelerate the development of new therapies. Our initiatives media handles to share Our work is organised around three key initiatives that interact to deliver value and tangible benefits for people living with dementia and their care partners. your comments, feedback, The Australian Dementia Network The Australian Dementia The Australian Dementia Network Screening and Trials Program – Network Registry – A Clinical Memory Clinic Initiative - Cutting-edge specialist Quality Registry to drive harmonising the diagnostic diagnostics continuous quality standards of memory clinics experience of the improvement in clinical care The Australian Dementia Network The Australia Dementia Network Screening and Trials initiative is The Australian Dementia Network Memory Clinics initiative is working to creating opportunities for Australians Registry is a clinical quality registry harmonise the diagnostic standards of conference. living with dementia to access new for people newly diagnosed with memory clinics across Australia and therapies under development by either dementia or mild cognitive develop training, professional facilitating recruitment into clinical trials impairment. It collects data about development, and easily accessible https://twitter.com/ADF2021 https://www.facebook.com/ADF2021/ across Australia. It provides clinicians the diagnosis, clinical care and clinical resources for health with cutting-edge specialist diagnostic outcomes of this population. professional staff. techniques for eligible patients free of For more information: For more information: cost. If your organisation is interested in To list your clinic on our national list, For more information: participating in the Registry or you available online, please email To refer your patient to our program, would like more information, contact [email protected] contact [email protected] or Bi-monthly webinars - Watch past [email protected] 1800 314 421. webinars on our YouTube channel or Interested individuals can register to register via our website or our social participate in clinical trials – see media channels. https://www.australiandementianetw Or contact us at ork.org.au/i-am-a-member-of-the-pub [email protected] for more lic-or-consumer/volunteer-for-trials/ information. For more information, contact Dr Jo Robertson, our national ADNeT Screening and Trials coordinator, on [email protected] or 0408 508 121. Stay in touch www.australiandementianetwork.org.au @ADNeT_Australia Australian Dementia Network Faculty of Medicine, Dentistry and Health Sciences [email protected] Level 2, Alan Gilbert Building +61 3 9035 9635 The University of Melbourne Victoria 3010 Australia LISTEN TO WHAT THE FUTURE HAS TO SAY IN Join the new conversation with leaders, influencers, innovators and brilliant minds about the future of Alzheimer’s disease. For Australian Healthcare Professionals. ®Biogen is a registered trademark of Biogen MA Inc. Biogen Australia, Macquarie Park NSW. ©2021. Biogen-105259. BGAD21440W. Date of preparation: April 2021. 4 www.adf2021.org.au Australian Dementia Forum 2021 5 Sponsors Platinum Sponsor Gold Sponsor About NHMRC About Biogen NHMRC has been supporting health and medical research and advancing health At Biogen, our mission is clear: we are pioneers in neuroscience. Biogen and medical knowledge to improve the health of all Australians since 1937. discovers, develops, and delivers worldwide innovative therapies for people NHMRC’s mission is building a healthy Australia. living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. One of the world’s first global biotechnology As the Australian Government’s lead agency for funding health and medical companies, Biogen was founded in 1978 by Charles Weissmann, Heinz research, NHMRC invests in the creation of knowledge about the mechanisms Schaller, Kenneth Murray, and Nobel Prize winners Walter Gilbert and Phillip underlying health and disease and in the development of better ways to prevent Sharp. Today Biogen has the leading portfolio of medicines to treat multiple and treat ill health. We support the translation of evidence from research into sclerosis, has introduced the first approved treatment for spinal muscular public health policy and clinical practice, and we promote the highest standards atrophy, commercializes biosimilars of advanced biologics, and is focused of research ethics and integrity. on advancing research programs in multiple sclerosis and neuroimmunology, Alzheimer’s disease and dementia, neuromuscular disorders, movement We fund research across the spectrum from discovery to implementation disorders, ophthalmology, neuropsychiatry, immunology, acute neurology, and science. We balance the needs of the community, government and the research neuropathic pain. sector, supporting both investigator-initiated and priority-driven research. We understand the important contribution that health and medical research makes For more information, please visit www.biogen.com.au or www.biogen.co.nz to creating knowledge and improving lives. NHMRC is proud to support the 2021 Australian Dementia Forum (ADF 2021). The NHMRC National Institute for Dementia Research (NNIDR), delivered in partnership with Dementia Australia, closed on 30 June 2020 after a successful Gold Sponsor five years supporting the Australian dementia research sector and assisting with the delivery of the Australian Government’s Boosting Dementia Research Initiative (BDRI). About CSIRO NHMRC remains committed to supporting dementia research. For more CSIRO, Australia’s national science agency, is committed to solving the nation’s information, please visit the NHMRC dementia research webpage. greatest health challenges through innovative science and technology. The Australian e-Health Research Centre (AEHRC) is CSIRO’s digital health research program – enabling the digital transformation of healthcare to improve services and clinical treatment for Australians. The AEHRC works with collaborators across the healthcare system to improve diagnosis and treatment. In aged care, the AEHRC brings our expertise in biomedical imaging and genomics, to enable early precision healthcare in diagnosis and treatment, while our health service research develops technologies that support services for those living with dementia. For more information, please visit https://aehrc.com/ 6 www.adf2021.org.au Australian Dementia Forum 2021 7 Contents Virtual Sponsor About Actinogen Convenors Welcome ..............................................8 Actinogen Medical is developing novel therapies for neurological diseases associated with dysregulated Organising Committee .......................................... 10 brain cortisol. We are currently developing the lead compound, Xanamem™, as a promising new therapy for Alzheimer’s disease, Fragile X syndrome, and other neurological diseases. Xanamem’s novel mechanism Keynote Speakers ....................................................11 of action works by blocking the production of intracellular cortisol – the stress hormone – through the inhibition of the 11β-HSD1 enzyme in the brain. Actinogen is planning to commence multiple phase II trials Virtual Platform information .............................. 14 targeting improved cognition and other potential benefits. Attendee Participation ..........................................17 For more information visit www.actinogen.com.au Technical Support ....................................................17 Program ..................................................................... 19 Frequently Asked Questions ...............................20 Supporting Partners 8 www.adf2021.org.au Australian Dementia Forum 2021 9 Convenor Welcome Dear delegates, y The Hon Greg Hunt MP, Minister for Health, Due to COVID, travel bans, regular outbreaks and the for accepting our invitation to officially need to keep presenters and participants safe, we Welcome to the Australian Dementia Forum 2021. open the conference. chose to run ADF2021 as a fully virtual conference. While many of us prefer the experience of face-to- y presenters and keynote speakers, face participation, we do hope that you will enjoy It is just 2 weeks short of 2 years since the previous especially those who graciously accepted the conference and the many participation and Australian Dementia Forum was held in Tasmania, but to participate in live Q&A sessions despite networking opportunities that it offers. so much has changed in that time. time zone differences and some very early/late starts. COVID
Load more

Recommended publications
  • 3Rd Macquarie Neurodegeneration Meeting 28-29 OCTOBER 2020
    CENTRE FOR MOTOR NEURONEDISEASE RESEARCH Faculty of Medicine, Health and Human Sciences 3rd Macquarie Neurodegeneration Meeting 28-29 OCTOBER 2020 AN EVENT FOR AUSTRALIAN NEUROSCIENTISTS TO SHOWCASE THEIR RESEARCH AND TO STIMULATE CONVERSATION AND FOSTER COLLABORATION TO DEVELOP TREATMENTS FOR DISEASES INCLUDING MOTOR NEURON DISEASE, ALZHEIMER’S DISEASE, FRONTOTEMPORAL DEMENTIA, PARKINSON’S DISEASE AND OTHER DEGENERATIVE BRAIN DISORDERS. Our Sponsor We are incredibly thankful to our sponsor for their support of the Macquarie Neurodegeneration Meeting Gain a new perspective on the nervous system and accelerate discovery. Explore 10x Genomics Solutions for neuroscience in this short video. 2 Our Sponsor 3 Our Sponsor 4 Welcome The Macquarie Neurodegeneration Meeting is an annual event hosted by the Centre for Motor Neuron Disease Research, Macquarie University. The aim of this event is for Australian neuroscientists to showcase their research and to stimulate conversation and foster collaboration to develop treatments for diseases including motor neuron disease, Alzheimer’s disease, frontal temporal dementia, Parkinson’s disease and other degenerative brain disorders. We welcome your involvement and hope the day provides inspiration and assists in fostering collaboration and connections in the neurodegeneration research community. Yours Sincerely, The Conference Organising Committee COMMITTEE MEMBERS Centre for Motor Neuron Disease Research Professor Julie Atkin Co-Director Professor Ian Blair Co-Director Christina Cassidy Centre Administrator
    [Show full text]
  • The Brain and Mind Centre Optymise Cohort: Tracking Multidimensional Outcomes in Young People Presenting for Mental Healthcare
    Open access Cohort profile BMJ Open: first published as 10.1136/bmjopen-2019-030985 on 29 March 2020. Downloaded from Cohort profile: the Brain and Mind Centre Optymise cohort: tracking multidimensional outcomes in young people presenting for mental healthcare Joanne S Carpenter ,1 Frank Iorfino ,1 Shane Cross ,1,2 Alissa Nichles,1 Natalia Zmicerevska ,1 Jacob J Crouse ,1 Jake R Palmer ,1,3 Alexis E Whitton,1 Django White,1 Sharon L Naismith,1,2,4 Adam J Guastella,1 Daniel F Hermens ,1,5 Jan Scott ,1,6,7 Elizabeth M Scott ,1,8 Ian B Hickie 1 To cite: Carpenter JS, Iorfino F, ABSTRACT Strengths and limitations of this study Cross S, et al. Cohort profile: Purpose The Brain and Mind Centre (BMC) Optymise the Brain and Mind Centre cohort assesses multiple clinical and functional domains ► This cohort tracks longitudinally a large number of Optymise cohort: tracking longitudinally in young people presenting for mental health multidimensional outcomes in young people presenting for mental health care and care and treatment. Longitudinal tracking of this cohort will young people presenting for treatment early in the course of common mental allow investigation of the relationships between multiple mental healthcare. BMJ Open disorders. It will provide detailed information about outcome domains across the course of care. Subsets of 2020;10:e030985. doi:10.1136/ variations in the course of emerging illness over a have completed detailed neuropsychological bmjopen-2019-030985 Optymise prolonged, and developmentally sensitive, follow-up and neurobiological assessments, permitting investigation period. ► Prepublication history and of associations between these measures and longitudinal additional material for this ► Multiple clinical and functional outcome domains course.
    [Show full text]
  • Research Excellence
    Research excellence We are one of the world’s top research universities and a member of Australia’s prestigious Group of Eight network and the Association of Pacific Rim Universities. We also partner with others that excel in research, including Harvard, Stanford, Utrecht University, Tsinghua University and the University of Hong Kong. sydney.edu.au/research Our research is driven by the big such as health, climate change and − the Australian Institute for picture and we provide a hub for food security. Our multidisciplinary Nanoscale Science and industry, government and community research centres include: Technology that is transforming groups to collaborate with us and Sydney into a global hub for connect with our researchers and − the Charles Perkins Centre discovering and harnessing new students. The development of major dedicated to easing the global science at the nanoscale. innovations such as the black box burden of obesity, diabetes, recorder, pacemaker, Wifi and the cardiovascular disease We invest in research that changes bionic ear started here. and related conditions the way we think about the world. − the Brain and Mind Centre, a Find out more about our research: We are also home to 90 world- leader in research, education sydney.edu.au/research renowned multidisciplinary research and treatment of a range and teaching centres that are of diseases from autism to strongly positioned to tackle some schizophrenia, depression, of the world’s biggest challenges, dementia and Parkinson’s disease In the top 50 All our research We are tripling of the world’s best is ranked at world our investment in CRICOS 00026A CRICOS research universities standard or above research (QS World University (Excellence in Research for (University of Sydney Rankings 2018) Australia report, 2015) Strategic Plan, 2016-20 ) – POSTGRADUATE RESEARCH HOW TO APPLY HOW TO APPLY RESEARCH These steps will guide you in applying for a research – master's or PhD degree at the University of Sydney.
    [Show full text]
  • BMJ Open Is Committed to Open Peer Review. As Part of This Commitment We Make the Peer Review History of Every Article We Publish Publicly Available
    BMJ Open: first published as 10.1136/bmjopen-2020-046830 on 7 July 2021. Downloaded from BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available. When an article is published we post the peer reviewers’ comments and the authors’ responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to. The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript. BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (http://bmjopen.bmj.com). If you have any questions on BMJ Open’s open peer review process please email [email protected] http://bmjopen.bmj.com/ on September 27, 2021 by guest. Protected copyright. BMJ Open BMJ Open: first published as 10.1136/bmjopen-2020-046830 on 7 July 2021. Downloaded from Repetitive transcranial magnetic stimulation (rTMS) in autism spectrum disorder: protocol for a multicentre randomised controlled clinical trial ForJournal: peerBMJ Open review only Manuscript ID bmjopen-2020-046830 Article Type: Protocol Date Submitted by the 11-Nov-2020 Author: Complete List of Authors: Enticott,
    [Show full text]
  • Measuring Social Anxiety in Adults with Autism Spectrum Disorder: Psychometric
    Running head: PSYCHOMETRIC PROPERTIES OF SOCIAL ANXIETY MEASURES IN ASD Measuring Social Anxiety in Adults with Autism Spectrum Disorder: Psychometric Properties of Self-Report Instruments Authors: Kelsie A. Boulton1,2, & Adam J. Guastella1,2 1. Autism Clinic for Translational Research, Brain and Mind Centre, Children’s Hospital Westmead Clinical School, Faculty of Medicine and Health, University of Sydney, Camperdown, New South Wales, 2050, Australia. 2. Child Neurodevelopment and Mental Health Team, Brain and Mind Centre, Children’s Hospital Westmead Clinical School, Faculty of Medicine and Health, University of Sydney, Camperdown, New South Wales, 2050, Australia. Please address correspondence to: Prof Adam Guastella Brain & Mind Centre The University of Sydney 100 Mallett Street Camperdown, NSW 2050 Australia [email protected] PSYCHOMETRIC PROPERTIES OF SOCIAL ANXIETY MEASURES IN ASD 2 Abstract Adults with autism spectrum disorder (ASD) are at elevated risk for social anxiety disorder (SAD). Limited information exists on the appropriateness of using social anxiety instruments with these adults. This study examines psychometric properties of self-report social anxiety instruments in autistic adults without intellectual disability, compared to adults with SAD. Additionally, we compared instrument scores between autistic adults with a dual diagnosis of SAD and adults with SAD only. Adults diagnosed with SAD (N=316) or ASD (N=102) were recruited from the Brain and Mind Centre in New South Wales, Australia. Sixty autistic participants received a diagnosis of SAD. Participants completed the Liebowitz Social Anxiety Scale-self-report, the Social Interaction Anxiety Scale, the Social Phobia Scale, and the Brief Fear of Negative Evaluation Scale. All instruments showed excellent internal consistency in autistic adults.
    [Show full text]
  • Brain and Mind Centre Annual Report
    Our sydney.edu.au Brain and Mind Centre Annual Report 2015-16 patients’ success sydney.edu.au/brain-mind sydney.edu.au/brain-mind 0774 2 9351 +61 The University of Sydney Contact us is our greatest reward. Forest Stewardship Council (FSC®) is a globally recognised certification Forest Stewardship Council (FSC®) is a globally recognised certification overseeing all fibre sourcing standards. This provides guarantees for the consumer that products are made of woodchips from well-managed forests and other controlled sources with strict environmental, economical and social standards. Contents Welcome ............................................ 2 Co-Directors...........................................2 Message from Vice Chancellors ...............3 - Overview ............................................ 4 Teams and key research themes ..............4 Partnerships ...........................................6 - Child Development and Behaviour ......... 8 Our core business ...................................9 Highlights .............................................. 10 Key projects and clinical trials ............... 12 2017 and beyond ................................... 13 Key publications .................................... 14 - Youth Mental Health ............................ 18 Our core business ................................. 18 Brain and Mind Centre Annual Report 2015-16 Highlights ..............................................20 2017 and beyond ...................................22 Key projects and clinical trials ..............23 Key
    [Show full text]
  • The University of Sydney Health and Wellness
    The University of Sydney Health and Wellness Presented by Dr Sarah Robbins Faculty of Medicine and Health Institute of Bone and Joint research The University of Sydney Page 1 Why collaborate with The University of Sydney? Established in 1850, we are Australia’s first university. – Today we are ranked in the world’s top 50 universities. – More than 20 of our subjects are ranked in the world’s top 30. – Our research in every area is ranked as performing at world standard or above. Last year we received more than $350 million in government funding for research. – We currently have 60,000 students including nearly 26,000 international students from more than 130 countries. The University of Sydney Page 2 – 320,000+ alumni in more than 170 countries. Who do we currently collaborate with? The University of Sydney Page 3 What are we doing about? – We are tripling our research investment to $150 million per year by 2020 to enable our academic staf to improve the lives of people in Australia and around the world. – Since 2011 we have invested more than $1.7 billion in exceptional facilities, and we are home to a cluster of research centres that supports multidisciplinary, collaborative projects. – By 2020, we aim to give 50 percent of our students the opportunity to study overseas during their degree. The University of Sydney Page 4 Our world-class research centres – The Charles Perkins Centre is dedicated to easing the global burden of obesity, diabetes and cardiovascular disease. – Sydney Nano is transforming our city into a global hub for discovering and harnessing new science at the nanoscale.
    [Show full text]
  • Brain Communications Ain Communications
    doi:10.1093/braincomms/fcaa235 BRAIN COMMUNICATIONS 2021: Page 1 of 8 | 1 BRAINAIN COMMUNICATIONSCOMMUNICATIONS Cerebrospinal fluid liquid biopsy for detecting Downloaded from https://academic.oup.com/braincomms/article/3/1/fcaa235/6105078 by University of Melbourne user on 26 March 2021 somatic mosaicism in brain Zimeng Ye,1 Zac Chatterton,2 Jahnvi Pflueger,3,4 John A. Damiano,1 Lara McQuillan,1 Anthony Simon Harvey,5,6,7 Stephen Malone,8 Hongdo Do,9,10,11 Wirginia Maixner,12 Amy Schneider,1 Bernadette Nolan,8 Martin Wood,13 Wei Shern Lee,5,6 Greta Gillies,5,6 Kate Pope,5 Michael Wilson,5,6 Paul J. Lockhart,5,6 Alexander Dobrovic,10,11,14,* Ingrid E. Scheffer,1,5,6,7 Melanie Bahlo,15,16 Richard J. Leventer,5,6,7 Ryan Lister,3,4 Samuel F. Berkovic,1,† and Michael S. Hildebrand1,5,† * Present address: Department of Medicine (Austin Health), Translational Genomics and Epigenomics Laboratory, University of Melbourne, Melbourne, Victoria 3084, Australia † These authors contributed equally to this work. Brain somatic mutations are an increasingly recognized cause of epilepsy, brain malformations and autism spectrum disorders and may be a hidden cause of other neurodevelopmental and neurodegenerative disorders. At present, brain mosaicism can be detected only in the rare situations of autopsy or brain biopsy. Liquid biopsy using cell-free DNA derived from cerebrospinal fluid has detected somatic mutations in malignant brain tumours. Here, we asked if cerebrospinal fluid liquid biopsy can be used to detect somatic mosaicism in non-malignant brain diseases. First, we reliably quantified cerebrospinal fluid cell-free DNA in 28 patients with focal epilepsy and 28 controls using droplet digital PCR.
    [Show full text]
  • Witness Statement of Professor David Leon Copolov Ao
    WIT.0001.0184.0001 Royal Commission into Victoria's Mental Health System WITNESS STATEMENT OF PROFESSOR DAVID LEON COPOLOV AO I, David Leon Copolov, Professor of Psychiatry, Monash University and Pro-Vice-Chancellor, Major Campuses and Student Engagement, of Monash University, Wellington Road, Clayton, Victoria 3800, say as follows: I make this statement in my private professional capacity as a psychiatrist, academic and former researcher, the long-standing Executive Director of the Mental Health Research Institute of Victoria (from 1985-2004) and my previous governance experience as a Director of the Board of the Royal Women’s Hospital (my term having ended on 30 June 2020) and on the Board of the Peter MacCallum Cancer Centre, with six years (2007- 2013) as Deputy Chairman of that Board and five years (2005-2010) as Chair of the Research Committee of that Board. My experience, since 2009, in Senior Management at Monash University, Australia’s largest university, has also guided my views and recommendations about ‘big system’ reform in the area of mental health. My opinions are not to be interpreted as being provided on behalf of Monash University, the University of Melbourne or any other institution or organisation that I am or have been associated with. 2 As detailed below, I do not have experience on the frontline of the public mental health system. However, I have had extensive peer contact with colleagues in the public mental health system, and am an ardent (but unappointed) advocate for those who are served by and who work in that system. I am also an aggregator of information from people associated with and documentary sources relating to the Victorian public mental health sector.
    [Show full text]
  • Non-Government Funding for Victorian Health and Medical Research About Research Australia
    NON-GOVERNMENT FUNDING FOR VICTORIAN HEALTH AND MEDICAL RESEARCH ABOUT RESEARCH AUSTRALIA OUR VISION: Research Australia envisions a world where Australia unlocks the full potential of its world-leading health and medical research sector to deliver the best possible healthcare and global leadership in health innovation. OUR MISSION: To use our unique convening power to position health and medical research as a significant driver of a healthy population and contributor to a healthy economy. OUR ROLE: CONNECT researchers, funders and consumers to increase investment in health and medical research from all sources. ENGAGE Australia in a conversation about the health benefits and economic value of its investment in health and medical research. INFLUENCE government policies that support effective health and medical research and its routine translation into evidence-based practices and better health outcomes. ACKNOWLEDGMENT: Research Australia acknowledges the support of the Victorian Government Department of Health and Human Services in the preparation of this report. This document and the ideas and concepts set out in this document are subject to copyright. No part of this document, ideas or concepts are to be reproduced or used either in identical or modified form, without the express written consent of Research Australia Limited ABN 28 095 324 379. Published December 2018 2 RESEARCH AUSTRALIA Non-government funding for Victorian Health and Medical Research 3 3 GLOSSARY ACNC Australian Charities and Not-for-profits Commission CAH Charity Advancing Health - a subtype of charity, used by the ACNC to register charities GDP Gross Domestic product - a measure of value of economic activity HPC Health Promotion Charity - a subtype of charity, used by the ACNC to register charities.
    [Show full text]
  • CHIEF EXECUTIVE OFFICER Australian National Imaging Facility
    CHIEF EXECUTIVE OFFICER Australian National Imaging Facility Closing date: April 11, 2021 Administering organisation Nodes of NIF CONTENTS Letter from the Chair, NIF Board 3 About the Australian National Imaging Facility 4 NIF Governance and Management 7 Duty Statement 8 How to Apply 10 The University of Queensland: Administering Organisation of NIF 11 Why choose Brisbane, Australia? 12 LETTER FROM THE CHAIR, AUSTRALIAN NATIONAL IMAGING FACILITY (NIF) BOARD On behalf of the Board of NIF, and the Administering Organisation, the University of Queensland, I have great pleasure in inviting applications for the appointment as the Chief Executive Officer of NIF. NIF provides state-of-the-art imaging capabilities that support world-class science for the Australian research and innovation communities. The facility provides critical infrastructure and capability to address national and global challenges in medicine, human health, food security and new materials. NIF is looking for an innovative, collaborative, inclusive and inspiring leader to lead the next stage of the organisation’s development. The successful candidate will be a strategic thinker, with strong business acumen, able to harness diverse interests, with experience in delivering outcomes at scale. He or she will have a proven track record of building collaborative partnerships with various stakeholders, and a deep understanding of navigating the nuances of Government, academia and industry. A science and technology background that provides the basis for strong and influential engagement with the imaging community and outstanding and persuasive communication and presentation skills are essential for the role. The successful candidate will be expected to play a significant national and international role to promote NIF especially in solving current and emerging national priorities in the post COVID social and economic recovery.
    [Show full text]
  • 113 a Case of Suspected Autoimmune Encephalitis Secondary to Nivolumab
    Abstracts J Neurol Neurosurg Psychiatry: first published as 10.1136/jnnp-2019-anzan.100 on 29 July 2019. Downloaded from Results Out of the 235 patients that were reviewed, 71 112 AXONAL POLYNEUROPATHY WITH ONSET IN YOUNG patients either received thrombolysis and/or were sent for ADULTHOOD DUE TO TUBB3 MUTATION endovascular treatment, and 164 patients were not suitable for Po Sheng Yang*, Kimberley K Forrest, Ian B Wilson. Neurology, Cairns Base Hospital, hyperacute treatment. Using the triage tool, we identified that Cairns, QLD, Australia 26% (n=61) of the rapid clinical assessment and 32% (n=42) of CT perfusion scans performed could have been avoided. 10.1136/jnnp-2019-anzan.99 Conclusion Use of a web-based triage tool is not only effective to identify patients suitable for hyperacute management but Introduction The TUBB3 gene encodes the protein Beta-tubu- also to avoid over-investigation and prioritize rapid neurologi- lin isotype III, a component of the microtubule cytoskeleton. cal clinical assessments. Mutations in this gene have been associated with axonal poly- neuropathy, however usually associated with congenital fibrosis of the extraocular muscles (CFOEM) and other abnormalities of cerebral development.12We report a case of isolated neu- 111 RECURRENT HEADACHES WITH PSYCHOSIS, CSF ropathy associated with a TUBB3 mutation. LYMPHOCYTOSIS, VESSEL BEADING AND Methods Case report - clinical information and next genera- PAPILLOEDEMA- AUTOIMMUNE/VIRAL ENCEPHALITIS tion sequencing results were obtained. WITH VASCULOPATHY OR UNUSUAL PRESENTATION OF Results A 64 year old man presented with a severe, progres- REVERSIBLE CEREBRAL VASOCONSTRICTION sive, length dependent sensorimotor polyneuropathy which SYNDROME (RCVS)? commenced in his late twenties.
    [Show full text]